Financial Statements
13. Non-operating result
The non-operating result for 2007 was minus €920 million (2006: minus €782 million), comprising an equity-method loss of €45 million (2006: €25 million), non-operating expenses of €1,709 million (2006: €1,688 million) and non-operating income of €834 million (2006: €931 million). Details on the individual categories of the non-operating result are provided below.
13.1. Income (loss) from investments in affiliated companies
This comprised the following:
| 2006 | 2007 | |
| € million | ||
| Net loss from investments in associates (equity-method loss) | (25) | (45) |
| Expenses | ||
| Write-downs of investments in affiliated companies | (20) | (27) |
| Losses from the sale of investments in affiliated companies | (12) | - |
| Income | ||
| Dividends from affiliated companies and income from profit and loss transfer agreements (net) | 5 | - |
| Gains from the sale of investments in affiliated companies | 259 | 3 |
| Total | 207 | (69) |
The income from investments in affiliated companies mainly comprised an equity-method loss of €48 million (2006: €55 million) from two production joint ventures with Lyondell. In 2006, this item also included equity-method income of €28 million received from GE Bayer Silicones prior to its divestiture, which itself contributed €236 million to income from investments in affiliated companies in that year.
Further details of the companies included at equity in the consolidated financial statements are given in Note [19] .
Further details of the companies included at equity in the consolidated financial statements are given in Note [19] .
13.2. Interest expense
This comprised the following:
| 2006 | 2007 | |
| € million | ||
| Expenses | ||
| Interest and similar expenses | (1,075) | (1,320) |
| Interest expense for derivatives (held for sale) | (306) | (107) |
| Income | ||
| Other interest and similar income | 394 | 612 |
| Interest income from derivatives (held for sale) | 259 | 114 |
| Total | (728) | (701) |
This item includes interest expense of €32 million (2006: €45 million) relating to non-financial liabilities and interest income of €1 million (2006: €16 million) from non-financial assets.
The portion of net income or loss attributable to minority stockholders to whom the company has a repayment obligation out of total assets is reflected in net interest expense. In this context income of €2 million was recorded as interest expense for the year under report (2006: €26 million interest income).
The portion of net income or loss attributable to minority stockholders to whom the company has a repayment obligation out of total assets is reflected in net interest expense. In this context income of €2 million was recorded as interest expense for the year under report (2006: €26 million interest income).
13.3. Other non-operating expense
Other non-operating income and expense comprised the following:
| 2006 | 2007 | |
| € million | ||
| Expenses | ||
| Interest portion of interest-bearing provisions | (223) | (246) |
| Exchange loss | (18) | - |
| Miscellaneous non-operating expenses | (34) | (9) |
| Income | ||
| Exchange gain | - | 88 |
| Miscellaneous non-operating income | 14 | 17 |
| Total | (261) | (150) |
The interest portion of noncurrent interest-bearing provisions mainly relates to pension provisions.
back to overview
back to overview


Chairman’s Letter
Notes
Bayer Links
Investor Relations

Bookmark this page
E-mail this page
Advanced Search

